UMM Logo

Universitas Muhammadiyah Malang


Free Download Journals Directory


International Journal of Medical Sciences

.: Home > International Journal of Medical Sciences > 2008 > Volume 5 Number 5 > Anne-Sophie Maisonneuve 1, 2, Laetitia Huiart 1, 2, Laetitia Rabayrol 1, 2, Doug Horsman 3, Remi Didelot 4, Hagay Sobol 1, 2, Francois Eisinger 1, 2, 3

Acceptability of cancer chemoprevention trials: impact of the design

Anne-Sophie Maisonneuve 1, 2, Laetitia Huiart 1, 2, Laetitia Rabayrol 1, 2, Doug Horsman 3, Remi Didelot 4, Hagay Sobol 1, 2, Francois Eisinger 1, 2, 3
1. Institut Paoli-Calmettes, Department of Oncogenetics Prevention and Screening Marseille France (FE, ASM, LH, LR, HS) 2. INSERM U 599, Marseille France (FE, ASM, LH, LR, HS) 3. Hereditary Cancer Program British Colombia Cancer Agency (FE, DH) 4. Local Administration of the National Health Insurance System – “Centre d’Examen de Sante (CESAM 13) ” Marseille France (RD)
Abstract :

Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and
risk/benefit balance is at best achieved through randomized clinical trials. Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials. Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more)
were far less acceptable: 9.2% for lung cancer (OR=7.7 CI95% 4.4-14.0) and 10.5 % for breast cancer   (OR=6.9 CI95% 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI95% 3.6-12.9). Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate.

Keywords :
Research Design, Randomized Controlled Trials, Behavior, Attitude, Preventive Health Services, Prevention & Control, Neoplasms, Breast, Lung

Date Deposited : 28 Jul 2011 11:17

Last Modified : 28 Jul 2011 11:17

Official URL: http://www.medsci.org/archive

Volume 5, Number 5, - 2008 , ISSN 1449-1907

Download:
Full Text Original
Abstract : pdf doc
Home | Peta Situs | Admissions | Student Research | E-Journal
Universitas Muhammadiyah Malang © 2011
Developed by Infokom UMM
Last Update : 13 December 2016 20:46Kumpulan file jurnal